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Summary Cell viability following short (1 h) contact with paclitaxel or docetaxel was assayed using syn-
chronised HeLa cells. Docetaxel proved almost totally lethal against S-phase cells. Its toxicity was only partial
against cells in mitosis. and declined to a minimum with progression to GI. For paclitaxel. cytotoxicity
increased with progression through S and G,, peaked at the time of mitosis. and decreased thereafter.
Maximum resistance to paclitaxel was in early S. Although lethal, brief exposure to docetaxel in S-phase did
not delay progression through S and G2. Gross damage was detectable immediately after mitosis, with
dysfunction in cytokinesis and accumulation of multinucleated, non-viable cells. Arrest of cells at pro-
metaphase required continuous contact with lethal amounts of docetaxel or reintroduction of drug shortly
before mitosis following pulse-chase treatment in mid-S-phase. Paclitaxel at moderate doses presumably acts
mostly via damage to the mitotic spindle. In contrast, the available data suggest that docetaxel primarily
targets centrosome organisation. leading to abortive mitosis and cell death.
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Paclitaxel (Taxol) and docetaxel (Taxotere) are the first of a
new class of microtubule-targeting anti-tumour diterpenoids
currently referred to as taxoids (Figure 1). Paclitaxel (PAC)
was first isolated from the bark of the Pacific yew Taxus
brevifolia (Wani et al., 1971). Docetaxel (DOC) is a new
taxoid obtained from chemical synthesis from 10-
deacetylbaccatin III, a taxoid extracted from a renewable
source, the needles of the English yew Taxus baccata (Man-
gatal et al., 1989; Gueritte-Voegelein et al., 1991). PAC and
DOC are highly cytotoxic against proliferating mammalian
cells in vitro (Hanauske et al., 1992; Kelland and Abel, 1992;
Riou et al., 1992). DOC reportedly cures transplantable
tumours in mice (Bissery et al., 1991), and both PAC and
DOC have proved active in the treatment of ovarian, breast
and lung cancer in humans (Extra et al., 1993; Rowimsky et
al., 1992).
The elucidation of the mode of action of taxoids is of great
interest in consideration of their promising anti-tumour
potential. PAC in the micromolar range is a promoter of
tubulin polymenrsation, thus decreasing the critical concentra-
tion of tubulin required for the self-assembly of microtubules
(Schiff et al., 1979) in the absence of microtubule-associated
proteins and of GTP (Schiff and Horwitz, 1981). PAC also
stabilises microtubules against disruption by nocodazole
(Amin-Hanjani et al., 1991), by calcium chloride (Thompson
et al., 1981) and by cold in the test tube and in cells (Schiff et
al., 1979; Schiff and Horwitz, 1980). Finally, PAC binds
specifically and reversibly to polymenrsed forms of tubulin
with stoichiometry close to unity (Parness and Horwitz,
1981), promotes the reorganisation of the microtubule net-
work into dense bundles or asters (De Brabander et al.,
1981a; Roberts et al., 1989) and induces complex arrays of
cross-bridged microtubules and intermediate filaments
(Geuens et al.. 1983; Green and Goldman, 1983). DOC
produces the same effects as PAC on the microtubule system,
yet it appears more potent than PAC on a molar basis
(Gueritte-Voegelein et al., 1991; Ringel and Horwitz, 1991;
Horwitz, 1992; Diaz and Andreu, 1993). These effects have
been proposed to play a major role in the antineoplastic
activity of PAC (Rowinsky et al., 1988); however, they are
not observed unless cells are exposed for extended lengths of
time to supralethal amounts of drug (Amin-Hanjani et al.,
1991). and attempts at identifying the mode of action of
taxoids in living cells from studies in the test tube should
take into consideration the capability of cells to accumulate
these drugs in large excess over the medium (Jordan et al.,
1993; Riou et al., 1994).
Exposure of human cells to PAC brings about a sustained
block at the metaphase-anaphase boundary. This again
requires prolonged, continuous contact with lethal amounts
of drug, and large differences in the efficiency of the mitotic
block occur among cell lines (Gupta, 1985; Roberts et al..
1990); in some instances drug-treated cells escape the mitotic
block without cytokinesis and give rise to multinucleated,
non-viable cells (Jordan et al., 1993). We thought that using
pulse (1 h) exposure to amounts of drugs in the range of the
ICs, values might shed some light on the mode of action of
taoids, in particular on the cell cycle phase dependence of
the cytotoxicity of drugs. HeLa cells were chosen because of
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the ease with which they can be synchronised at GI-S using a
double-thymidine block technique (Bjursell and Reichard.
1973). We show here that PAC and DOC exhibit pronounced
differences in their cell cycle phase specificity for cell killing.
Materials and methods
Reagents
Thymidine. 5-bromo-2'-deoxyuridine. propidium iodide and
vinblastine were from Sigma. Rat monoclonal antibody
directed against 5-bromo-2'-deoxyuridine and fluorescein
isothiocyanate-conjugated goat anti-rat IgG were from Cera-
Lab and Southern Biotechnology Associates respectively.
PAC (NSC 125973) and DOC (RP 56976; NSC 628503) were
obtained from Rh6ne-Poulenc Rorer and stored as 10mM
sterile solutions in absolute ethanol at -20°C. Both drugs
were adjusted extemporarily at the required concentrations
by sequential dilutions in pure dimethylsulphoxide (DMSO)
and finally in growth medium with vortexing. The final con-
centraion of DMSO was kept low enough ( S 0.5%) in order
not to affect the growth of cells. [Propionyl-3-'4]DOC
(Departement des Molecules Marquees. CEA; specific
activity 47 mCi mmol-') was supplied as an ethanolic solu-
tion by Rh6ne-Poulenc Rorer and was stored at -80°C. All
products for cell culture were from Gibco-BRL.
Cell cultures
Human cervix carcinoma HeLa cells were subcultured and
grown as monolayers in Dulbecco's modified Eagle minimal
essential medium as described elsewhere (Hennequin et al..
1994).
Synchronisation of HeLa cells was achieved using a
double-thymidine block technique in the same way as des-
cribed by Tsao et al. (1992).
Treatments
For colony formation assays, 600-1200 cells from 4-day-old
mid-log phase subcultures were plated in tnpphcate or more in
25 cm2 flasks, and allowed to adhere and spread for 4 h in
the incubator before treatment. Following drug exposure, the
flasks were rinsed and cells returned to normal growth
medium for 10-11 days. Colonies were fixed with methanol.
stained and scored visually.
For determination of the growth-inhibitory effect of drugs.
1- to 2-day-old exponentially growing cultures (c. I0$ cells
cm-2) were exposed to drug. washed and incubated in drug-
free medium for 5 days. Colonies were then dislocated by
trypsin. cells were collected by centrifugation. resuspended
and scored with a model 256 Coulter counter.
Exposure to PAC or DOC was carried out in dim light to
prevent photodegradation of the drugs. Contact with either
drug was for I h. unless otherwise stated. Drugs were
carefully removed by two washes with Hanks' balanced
saline (37C) at 3-4 min intervals and cells were returned to
normal growth medium.
U'ptake and efflux ofDOC
Incorporation and release of DOC were probed using
[propionyl-3-'4C]DOC at concentrations ranging between
20 nM (0.94 nCi ml-') and 200 nM (9.4 nCi ml-') and cell
densities of 4 x 104 to 8 x I0 cells cm-' (25 cm- flasks). Fol-
lowing contact with drug for the desired times (up to 4 h).
the flasks were carefully rinsed twice with 10 ml of warm
Hanks' balanced saline solution. and once with complete
growth medium. Flasks were rinsed again before lysis. Lysis
was achieved by addition of 2 ml of 50 mM Tris-HCl. 2%
lauryl sulphate solution. pH 7.8. and the lysates counted by
scintillation. Cells were scored using replicate samples grown
and treated in parallel.
Where required. depolymerisation of microtubules before
contact with DOC was achieved in the same way as described
for P-388 cells (Riou et al., 1994). namely vinblastine
(31tg ml-')) was introduced 2 h before DOC. and was pres-
ent during DOC treatment (1 h). Cell survival was deter-
mined for each treatment applied alone or in combination.
Cvtofluorimetric analysis and data handling
Cell cycle progression was monitored by bivariate flow
cytometry as previously described (Hennequin et al.. 1994).
In experiments using synchronised cells. corrections for cel-
lular multiplicity were performed for the same reasons and in
the same way as reported previously (Hennequin et al..
1994).
Results
Cell c!ycle redistribution by DOC
Alteration of the cell cycle progression of asynchronous
growing HeLa cells upon continuous contact with DOC was
first investigated by bivariate flow cytometry for comparison
with data published on PAC. Some of the results are shown
in Figures 2 and 3. At large enough doses. DOC induced
accumulation of cells at a premitotic stage with depletion of
the GI and S-phase compartments. At 20 nM DOC. GI
depletion was completed after 14 h of treatment, but integral
S-phase depletion and mitotic arrest required 24 h incuba-
tion. Few cells only escaped the mitotic block. This picture
did not change appreciably after 30 h of contact with drug.
but substantial amounts of cell debris accumulated after 36 h.
Virtually all cells, therefore. were blocked (prometaphase)
within one doubling time (Figure 3). However. the concentra-
tion of DOCC required to reach this effect (20 nM) was about
20-fold as large as the IC; value determined from clonogenic
assays (data not shown), and no survivor was left after
treatment.
Incorporation and release of DOC
HeLa cells were found to accumulate large amounts of
[propionyl-3-'4C]DOC. up to 400-fold in excess over the
medium. Uptake and release were half over in c. 35 mmn and
5.2 ± 0.3 h respectively. Drug efflux was biphasic, with a
minor (c. 15%) component lasting less than 30 mn and a
major component (c. 85%) with tl 2 = 6.8 ± 0.4 h (data not
shown). Once corrected for cell multiplicity, the uptake of
DOC (1 h exposure) showed only minor changes with pro-
gression of synchronised HeLa cells through the cell cycle for
over one doubling time following release from double
thymidine block.
Microtubule depolymerisation by pretreatment with vin-
blastine (see Materials and methods) reduced DOC uptake to
15% of controls. Residual survival, however, was equal to
the product SDOC X SN-LB. of the surviving fractions deter-
mined for each treatment applied alone.
Cvtotoxicitv studies in asynchronous cultures
To establish a cytotoxic range for PAC and DOC. mid-log
proliferating HeLa cells were exposed to either drug and the
cell viability was assessed using clonogenic assays. The results
for 1 h drug exposure are shown in Figure 4. Cell survival
followed an exponential dose-effect relationship with both
drugs. The ICfo value. i.e. the amount of drug that reduces
the proliferation of treated cells to 50% of that of controls.
was in the range of 1O nM (DOC) to 225 nM (PAC).
Increasing the length of contact with drug resulted in a
steep fall in cell survival. For example, the IC_% for 24 h
exposure to DOC was reduced by as much as 35-fold com-
pared with that for a 1 h contact.
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Cell cycle phase dependence ofdrug c,totoxicity
PAC and DOC. each at doses close to the IC50 values
determined above (Figure 4), showed dissimilar responses in
assays using synchronised HeLa cells (Figure 5). DOC pro-
ved almost totally lethal against S-phase cells. Its toxicity was
not as absolute against mitotic cells, and declined to a
minimum as cells escaped M and progressed to GI phase.
The toxicity of PAC was comparatively low in early S, then
increased gradually as cells progressed through S and G,,
peaked at the time of mitosis and decreased again in the next
G, phase.
Pulse-chase treatment by DOC in early S phase entailed no
delay in progression through S and G, compared with con-
trols. but the bulk of DOC-treated cells concertedly
experienced aberrant mitosis without cytokinesis. ending in
formation of multinucleated, rounded cells which rapidly
detached from the surface of the flasks and died. This
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appears to be a major characteristic of the lethal mechanisms
induced by DOC. Among cells exposed to PAC in mid-S
phase. only some, in proportion to the cytotoxic potential of
the drug at the stage considered, experienced the same fate.
Thus, although fatal to cells. brief treatment with 10-30
nM DOC in mid-S-phase was not able to bring about the pre
mitotic block observed upon permanent contact with drug.
This was achieved, however, when DOC (20 nM) was re-
introduced 1 h before mitosis and subsequently left per-
manently in the medium.
Permanent contact with DOC blocks cell cycle progression of
growing HeLa cells at prometaphase. The time dependence
of this process (Figures 2 and 3) matches exactly that known
for PAC (Jordan et al., 1993; Lopes et al., 1993), in spite of
the large difference in the IC,o range for both drugs (Figure
4). In contrast. PAC and DOC given in short incubation
demonstrate large differences in the cell cycle phase specificity
of their cytotoxic potential against synchronised HeLa cells
(Figure 5). The toxicity of DOC against S-phase cells is
nearly absolute, with characteristic formation of multi-
nucleated cells hours after drug exposure, at the time cells
traverse mitosis. Hence, short contact with DOC in S phase
l th f oorntactwihd la1 (h)
Fige 3 Time and drug concentration dependence of arrest at
prometaphase in HeLa cells incubated in the presence of
docetaxel. The proportion of arrested cells was determined by
flow cytometry in the same way as described in the legend to
Figure 2.
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Figure 2 Cell cycle phase redistribution of growing. asyn-
chronous HeLa cells by continuous exposure to DOC for 9 h (a).
14 h (b) or 24 h (c). Cells were fixed at the times indicated
following pulse-labelling with 5-bromo-2'-deoxyuridine. and
subsequently analysed by bivanrate flow cytometry. The doubling
time of cells in drug-free medium was 22 ± I h.
0.0
Fire 4 Cytotoxic effect of pulse (60 min) treatment of asyn-
chronous. log-phase HeLa cells by PAC (0) or DOC (0. *).
Cells were either plated 4 h before drug exposure for colony
formation assays (0. 0) or treated with the drug 5 days before
trypsinisation and counting for determination of growth inhibi-
tion (0). The ICo was found to be 25.2 nM (DOC-) or 224 nM
(PAC.0) from the colony formation assay. The ICO for DOC in
the growth inhibition experiment (0) was 9.7 nM. Curves have
been drawn for best fit of experimental data to a single exponen-
tial model. Bars = s.d.
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Figure 5 Cytotoxic effect of 20 nM DOC (0) or 200 nM PAC
(0) against HeLa cells progressing synchronously through the
cell cycle following release from double thymidine block. Flow
cytometry (a) and survival assays (b) were carred out in parallel.
Mitosis peaked at exactly 9 h. Drugs were introduced at the times
indicated (b). Contact with drugs and 5-bromo-2'-deoxyuridine
was for 60 min and 15 min respectively. Survival data have been
corrected for cell multiplicity. Bars = s.d.
is lethal but not sufficient to block cells at a premitotic stage;
the block is not operating unless DOC is reintroduced shortly
before mitosis. This suggests that cell killing and arrest ofcell
cycle progression at prometaphase by DOC proceed from
distinct time-related mechanisms. Maximum toxicity of PAC
is at mitosis, in agreement with the findings of others
(Donaldson et al.. 1994; Geard and Jones, 1994; Long and
Fairchild, 1994), and consistent with the mitotic spindle
apparatus forming the main target of PAC. This occurs
irrespective of whether synchronisation of cells is achieved
using serum stimulation of quiescent cells (Donaldson et al..
1994), mitotic shake-off selection (Geard and Jones, 1994).
nocodazole treatment (Long and Fairchild, 1994) or double
thymidine block (Figure 5).
HeLa cells incorporate very large amounts of DOC in
excess over the medium, in the same way as reported with
PAC (Jordan et al., 1993). We consequently determined the
kinetics of drug uptake and efflux in order to address the
possibility that slow drug release would skew the sensitivity
profile of synchronised HeLa cells progressing through the
cell cycle. We found that the efflux of DOC is biphasic, with
a rapid, comparatively minor (15%) phase preceding slow
release of the major (85%) drug fraction. We tentatively
assign rapid efflux to a membrane compartment. The major
compartment presumably corresponds to tight binding of the
drug to microtubules (Riou et al., 1994); in fact, it disappears
after treatment of cells with vinblastine to induce
depolymerisation of the microtubule network. Whichever
mechanism, the time for efflux of 50% of incorporated
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[propionyl-3-'4CDOC out of HeLa cells is in the range of
5.2 ± 0.3 h. It is thus conceivable that, in cells treated in
S-phase, DOC persists in large enough amounts as the time
cells reach mitosis for it to alter the integrity of the mitotic
spindle apparatus and cause aberrant mitosis. The same
effect would not hold in the case of PAC. simply because the
efflux of PAC is rapid compared with that of DOC (Riou et
al., 1994).
However, this efflux model appears unable to account for
the S-phase specificity of DOC from several lines of evidence.
namely:
(1) Pulse exposure (I h) to DOC at the concentrations used
in our experiments is not sufficient to induce gross alteration
of the microtubule network and of the mitotic spindle (Jor-
dan et al., 1993). yet binding of taxoids seems to occur
preferentially on microtubules (Parness and Horwitz, 1981:
Riou et al., 1994) and could alter their dynamics (Jordan et
al., 1993).
(2) As shown in Figure 5. the toxicity of DOC introduced
at the time of mitosis. or shortly before, is not as absolute as
during S-phase.
(3) There is no change in the susceptibility to DOC
throughout S-phase.
(4) Drug uptake does not vary appreciably with progression
of cells through the cell cycle.
(5) Pulse-chase treatment with DOC at any time from early
to late S-phase, does not result in alteration of the cell cycle
progression for up to prometaphase.
Furthermore, despite slow drug efflux. S-phase-treated cells
will not arrest at prometaphase unless DOC is reintroduced
shortly before mitosis. We suggest. therefore. that in addition
to slower efflux kinetics. DO}C targets more efficiently and
more specifically than PAC some crucial system or organelle
whose expression or maturation occurs in S-phase. and
whose integrity would be essential to orderly progression
through mitosis and cytokinesis.
Centrosome, whose elongation in synchronised HeLa cells
extends throughout S-phase following separation of the
parent procentrioles in late GI (Robbins et al.. 1968:
Kuriyama and Borisy, 1981), appears to be the best can-
didate to meet these requirements (for a review see Tourmier
and Bornens. 1994). Centrosome targeting was already pro-
posed, years ago, to account for the S-phase specificity of
mitotic cell death induction by vinblastine (Madoc-Jones and
Mauro, 1968). Vinblastine and vincristine are inducers of
microtubule depolymerisation. but they may also promote
the formation of tubulin paracrystals (Na and Timasheff.
1982; Prakash and Timasheff. 1983; Skoda et al.. 1983). and
other authors have suggested that the cytotoxic effects of
Vinca alkaloids could be brought about by mechanisms up-
stream of the mitotic spindle formation (Jordan et al., 1991).
Damage to kinetochores is another possibility (De Brabander
et al., 1981b). In a forthcoming paper direct evidence will be
given, based on immunofluorescence staining in synchronised
HeLa cells, of hindered centrosomal function by DOC in
relation to cell cycle progression.
Abbreviations
PAC. paclitaxel; DOC. docetaxel.
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